
Angela DeMichele, MD, MSCE, discussed how the standard of care can be shifted based on the results of the phase 2 I-SPY2 trial investigating novel neoadjuvant treatment strategies in early breast cancer.
Your AI-Trained Oncology Knowledge Connection!
Angela DeMichele, MD, MSCE, discussed how the standard of care can be shifted based on the results of the phase 2 I-SPY2 trial investigating novel neoadjuvant treatment strategies in early breast cancer.
Based on findings from a real-world retrospective analysis, Stacey A. Cohen, MD, discussed the prognostic value of post-surgical minimal residual disease detection in patients with stage I to III colorectal cancer.
Findings from a pooled analysis indicated that a decrease in circulating tumor DNA was associated with improved clinical benefit in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.
Findings from a phase 2 clinical study indicated that neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab, and pertuzumab demonstrated promising efficacy and safety in the treatment of HER2-positive breast cancer.
Results from the phase 1/2 MajesTEC-1 trial highlighted sustained responses when teclistamab was used to treat patients with relapsed/refractory multiple myeloma who are triple refractory.
Patients with stage IVA to IVB nasopharyngeal carcinoma experienced an improvement in failure-free survival following treatment with paclitaxel, cisplatin, and capecitabine for 2 cycles vs 2 cycles of cisplatin and fluorouracil.
In patients with acute myeloid leukemia receiving venetoclax, tumor lysis syndrome was uncommon; patients at high risk should be admitted for venetoclax dosing ramp-up.
Investigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.
Hossein Borghaei, DO, MS, discussed where investigators may drive future research following the phase 2 Lung-MAP trial examining pembrolizumab and ramucirumab in previously treated advanced non–small cell lung cancer.
Routine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.
A supplement biologics license and a Type II variation were submitted to the FDA and European Medicines Agency, respectively, for first-line rucaparib in patients with advanced ovarian cancer.
Roy S. Herbst, MD, PhD, considers next steps in the management of patients with non–small cell lung cancer harboring genomic drivers.